Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection.

Forrest C, Hislop AD, Rickinson AB, Zuo J.

PLoS Pathog. 2018 Sep 24;14(9):e1007110. doi: 10.1371/journal.ppat.1007110. eCollection 2018 Sep.


Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.

Abbott RJ, Pachnio A, Pedroza-Pacheco I, Leese AM, Begum J, Long HM, Croom-Carter D, Stacey A, Moss PAH, Hislop AD, Borrow P, Rickinson AB, Bell AI.

J Virol. 2017 Oct 13;91(21). pii: e00382-17. doi: 10.1128/JVI.00382-17. Print 2017 Nov 1.


Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection.

Izawa K, Martin E, Soudais C, Bruneau J, Boutboul D, Rodriguez R, Lenoir C, Hislop AD, Besson C, Touzot F, Picard C, Callebaut I, de Villartay JP, Moshous D, Fischer A, Latour S.

J Exp Med. 2017 Jan;214(1):73-89. doi: 10.1084/jem.20160784. Epub 2016 Dec 23.


Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function.

Williamson SJ, Nicol SM, Stürzl M, Sabbah S, Hislop AD.

PLoS Pathog. 2016 Nov 28;12(11):e1006042. doi: 10.1371/journal.ppat.1006042. eCollection 2016 Nov.


Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs.

Woon HG, Braun A, Li J, Smith C, Edwards J, Sierro F, Feng CG, Khanna R, Elliot M, Bell A, Hislop AD, Tangye SG, Rickinson AB, Gebhardt T, Britton WJ, Palendira U.

PLoS Pathog. 2016 Aug 19;12(8):e1005799. doi: 10.1371/journal.ppat.1005799. eCollection 2016 Aug.


Primary B Lymphocytes Infected with Kaposi's Sarcoma-Associated Herpesvirus Can Be Expanded In Vitro and Are Recognized by LANA-Specific CD4+ T Cells.

Nicol SM, Sabbah S, Brulois KF, Jung JU, Bell AI, Hislop AD.

J Virol. 2016 Mar 28;90(8):3849-3859. doi: 10.1128/JVI.02377-15. Print 2016 Apr.


T-Cell Responses to EBV.

Hislop AD, Taylor GS.

Curr Top Microbiol Immunol. 2015;391:325-53. doi: 10.1007/978-3-319-22834-1_11. Review.


Early virological and immunological events in Epstein-Barr virus infection.

Hislop AD.

Curr Opin Virol. 2015 Dec;15:75-9. doi: 10.1016/j.coviro.2015.08.002. Epub 2015 Aug 31. Review.


Activation of DNA Damage Response Pathways during Lytic Replication of KSHV.

Hollingworth R, Skalka GL, Stewart GS, Hislop AD, Blackbourn DJ, Grand RJ.

Viruses. 2015 Jun 5;7(6):2908-27. doi: 10.3390/v7062752.


Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children.

Jayasooriya S, de Silva TI, Njie-jobe J, Sanyang C, Leese AM, Bell AI, McAulay KA, Yanchun P, Long HM, Dong T, Whittle HC, Rickinson AB, Rowland-Jones SL, Hislop AD, Flanagan KL.

PLoS Pathog. 2015 Mar 27;11(3):e1004746. doi: 10.1371/journal.ppat.1004746. eCollection 2015 Mar.


The immunology of Epstein-Barr virus-induced disease.

Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD.

Annu Rev Immunol. 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326. Epub 2015 Feb 11. Review.


Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.

Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD, Rowe M.

PLoS Pathog. 2014 Aug 21;10(8):e1004322. doi: 10.1371/journal.ppat.1004322. eCollection 2014 Aug.


A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells.

Lopez-Granados E, Stacey M, Kienzler AK, Sierro S, Willberg CB, Fox CP, Rigaud S, Long HM, Hislop AD, Rickinson AB, Patel S, Latour S, Klenerman P, Chapel H.

Clin Exp Immunol. 2014 Dec;178(3):470-82. doi: 10.1111/cei.12427.


Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory.

Rickinson AB, Long HM, Palendira U, Münz C, Hislop AD.

Trends Immunol. 2014 Apr;35(4):159-69. doi: 10.1016/ Epub 2014 Mar 1. Review.


IRF-4-mediated CIITA transcription is blocked by KSHV encoded LANA to inhibit MHC II presentation.

Cai Q, Banerjee S, Cervini A, Lu J, Hislop AD, Dzeng R, Robertson ES.

PLoS Pathog. 2013 Oct;9(10):e1003751. doi: 10.1371/journal.ppat.1003751. Epub 2013 Oct 31.


Suppression of antigen-specific T cell responses by the Kaposi's sarcoma-associated herpesvirus viral OX2 protein and its cellular orthologue, CD200.

Misstear K, Chanas SA, Rezaee SA, Colman R, Quinn LL, Long HM, Goodyear O, Lord JM, Hislop AD, Blackbourn DJ.

J Virol. 2012 Jun;86(11):6246-57. doi: 10.1128/JVI.07168-11. Epub 2012 Apr 4.


T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells.

Sabbah S, Jagne YJ, Zuo J, de Silva T, Ahasan MM, Brander C, Rowland-Jones S, Flanagan KL, Hislop AD.

Blood. 2012 Mar 1;119(9):2083-92. doi: 10.1182/blood-2011-07-366476. Epub 2012 Jan 10.


Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.

Zuo J, Thomas WA, Haigh TA, Fitzsimmons L, Long HM, Hislop AD, Taylor GS, Rowe M.

PLoS Pathog. 2011 Dec;7(12):e1002455. doi: 10.1371/journal.ppat.1002455. Epub 2011 Dec 22.


Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP.

Palendira U, Low C, Chan A, Hislop AD, Ho E, Phan TG, Deenick E, Cook MC, Riminton DS, Choo S, Loh R, Alvaro F, Booth C, Gaspar HB, Moretta A, Khanna R, Rickinson AB, Tangye SG.

PLoS Biol. 2011 Nov;9(11):e1001187. doi: 10.1371/journal.pbio.1001187. Epub 2011 Nov 1.


EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.

Horst D, Favaloro V, Vilardi F, van Leeuwen HC, Garstka MA, Hislop AD, Rabu C, Kremmer E, Rickinson AB, High S, Dobberstein B, Ressing ME, Wiertz EJ.

J Immunol. 2011 Mar 15;186(6):3594-605. doi: 10.4049/jimmunol.1002656. Epub 2011 Feb 4.


The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.

Zuo J, Quinn LL, Tamblyn J, Thomas WA, Feederle R, Delecluse HJ, Hislop AD, Rowe M.

J Virol. 2011 Feb;85(4):1604-14. doi: 10.1128/JVI.01608-10. Epub 2010 Dec 1.


Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.

Hislop AD, Palendira U, Leese AM, Arkwright PD, Rohrlich PS, Tangye SG, Gaspar HB, Lankester AC, Moretta A, Rickinson AB.

Blood. 2010 Oct 28;116(17):3249-57. doi: 10.1182/blood-2009-09-238832. Epub 2010 Jul 19.


Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection.

Sauce D, Larsen M, Abbott RJ, Hislop AD, Leese AM, Khan N, Papagno L, Freeman GJ, Rickinson AB.

J Virol. 2009 Sep;83(18):9068-78. doi: 10.1128/JVI.00141-09. Epub 2009 Jul 15.


Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.

Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD.

PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26.


Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.

Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, Rickinson AB, Wiertz EJ, Ressing ME.

J Immunol. 2009 Feb 15;182(4):2313-24. doi: 10.4049/jimmunol.0803218.


An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.

Bell MJ, Abbott RJ, Croft NP, Hislop AD, Burrows SR.

J Virol. 2009 Mar;83(6):2783-8. doi: 10.1128/JVI.01724-08. Epub 2009 Jan 7.


The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children.

Njie R, Bell AI, Jia H, Croom-Carter D, Chaganti S, Hislop AD, Whittle H, Rickinson AB.

J Infect Dis. 2009 Jan 1;199(1):31-8. doi: 10.1086/594373.


CD8+ T cell immunity to Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus.

Hislop AD, Sabbah S.

Semin Cancer Biol. 2008 Dec;18(6):416-22. doi: 10.1016/j.semcancer.2008.10.005. Epub 2008 Nov 1. Review.


Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow.

Palendira U, Chinn R, Raza W, Piper K, Pratt G, Machado L, Bell A, Khan N, Hislop AD, Steyn R, Rickinson AB, Buckley CD, Moss P.

Blood. 2008 Oct 15;112(8):3293-302. doi: 10.1182/blood-2008-02-138040. Epub 2008 Jul 17.


Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients.

Chaganti S, Ma CS, Bell AI, Croom-Carter D, Hislop AD, Tangye SG, Rickinson AB.

Blood. 2008 Aug 1;112(3):672-9. doi: 10.1182/blood-2007-10-116269. Epub 2008 May 28.


Synthesis and ex vivo profiling of chemically modified cytomegalovirus CMVpp65 epitopes.

Jones MA, Notta JK, Cobbold M, Palendira M, Hislop AD, Wilkie J, Snaith JS.

J Pept Sci. 2008 Mar;14(3):313-20.


A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.

Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, Croft NP, Neefjes JJ, Rickinson AB, Wiertz EJ.

J Exp Med. 2007 Aug 6;204(8):1863-73. Epub 2007 Jul 9.


Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Hislop AD, Taylor GS, Sauce D, Rickinson AB.

Annu Rev Immunol. 2007;25:587-617. Review.


IL-7R alpha versus CCR7 and CD45 as markers of virus-specific CD8+ T cell differentiation: contrasting pictures in blood and tonsillar lymphoid tissue.

Sauce D, Larsen M, Leese AM, Millar D, Khan N, Hislop AD, Rickinson AB.

J Infect Dis. 2007 Jan 15;195(2):268-78. Epub 2006 Dec 7.


The T cell response to persistent herpes virus infections in common variable immunodeficiency.

Raeiszadeh M, Kopycinski J, Paston SJ, Diss T, Lowdell M, Hardy GA, Hislop AD, Workman S, Dodi A, Emery V, Webster AD.

Clin Exp Immunol. 2006 Nov;146(2):234-42.


Synthesis and biological evaluation of two chemically modified peptide epitopes for the class I MHC protein HLA-B*2705.

Jones MA, Hislop AD, Snaith JS.

Org Biomol Chem. 2006 Oct 21;4(20):3769-77. Epub 2006 Sep 8.


Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution.

Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, van Baarle D, Egeler RM, van Tol MJ, Lankester AC.

Clin Infect Dis. 2006 Jun 15;42(12):1743-8. Epub 2006 May 4.


EBV-associated mononucleosis leads to long-term global deficit in T-cell responsiveness to IL-15.

Sauce D, Larsen M, Curnow SJ, Leese AM, Moss PA, Hislop AD, Salmon M, Rickinson AB.

Blood. 2006 Jul 1;108(1):11-8. Epub 2006 Mar 16.


Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation.

Thimme R, Appay V, Koschella M, Panther E, Roth E, Hislop AD, Rickinson AB, Rowland-Jones SL, Blum HE, Pircher H.

J Virol. 2005 Sep;79(18):12112-6.


Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance.

Hislop AD, Kuo M, Drake-Lee AB, Akbar AN, Bergler W, Hammerschmitt N, Khan N, Palendira U, Leese AM, Timms JM, Bell AI, Buckley CD, Rickinson AB.

J Clin Invest. 2005 Sep;115(9):2546-55. Epub 2005 Aug 18.


The impact of telomere erosion on memory CD8+ T cells in patients with X-linked lymphoproliferative syndrome.

Plunkett FJ, Franzese O, Belaramani LL, Fletcher JM, Gilmour KC, Sharifi R, Khan N, Hislop AD, Cara A, Salmon M, Gaspar HB, Rustin MH, Webster D, Akbar AN.

Mech Ageing Dev. 2005 Aug;126(8):855-65. Epub 2005 Apr 25.


Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens.

Zhou D, Li P, Lin Y, Lott JM, Hislop AD, Canaday DH, Brutkiewicz RR, Blum JS.

Immunity. 2005 May;22(5):571-81.


Virus-specific cytotoxic T lymphocytes differentially express cell-surface leukocyte immunoglobulin-like receptor-1, an inhibitory receptor for class I major histocompatibility complex molecules.

Antrobus RD, Khan N, Hislop AD, Montamat-Sicotte D, Garner LI, Rickinson AB, Moss PA, Willcox BE.

J Infect Dis. 2005 Jun 1;191(11):1842-53. Epub 2005 Apr 26.


HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

Midgley RS, Bell AI, Yao QY, Croom-Carter D, Hislop AD, Whitney BM, Chan AT, Johnson PJ, Rickinson AB.

J Virol. 2003 Nov;77(21):11507-16.


B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.

Moosmann A, Khan N, Cobbold M, Zentz C, Delecluse HJ, Hollweck G, Hislop AD, Blake NW, Croom-Carter D, Wollenberg B, Moss PA, Zeidler R, Rickinson AB, Hammerschmidt W.

Blood. 2002 Sep 1;100(5):1755-64.


Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential.

Dunne PJ, Faint JM, Gudgeon NH, Fletcher JM, Plunkett FJ, Soares MV, Hislop AD, Annels NE, Rickinson AB, Salmon M, Akbar AN.

Blood. 2002 Aug 1;100(3):933-40.


Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection.

Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB.

J Exp Med. 2002 Apr 1;195(7):893-905.

Supplemental Content

Loading ...
Support Center